Impact of Sequential Ramucirumab Plus Docetaxel After PD ‐1 Inhibitors on Anti‐ PD ‐1 Antibody‐Bound T‐Cell Dynamics and Clinical Outcomes

Documenti analoghi

• Authors' Reply to Letter to the Editor: Sequential Ramucirumab Plus Docetaxel After PD ‐1 Inhibitors
  di: Kinnosuke Matsumoto, et al.
  Pubblicazione: (2026)
• Real‐World Efficacy and Safety of Lenvatinib in Advanced or Recurrent Thymic Carcinoma: A Multicenter Retrospective Study in Japan
  di: Satoshi Miyamoto, et al.
  Pubblicazione: (2025)
• Exceptionally long‐lasting response to dabrafenib plus trametinib treatment in a patient with lung adenocarcinoma harboring the BRAF V600E mutation with high expression of PD‐L1: A case report
  di: Takako Inoue, et al.
  Pubblicazione: (2024)
• Identification of Hidden Cachexia Subgroup in PD‐L1‐High NSCLC: Comparative Analysis of the AWGC vs. Fearon Criteria
  di: Naoya Nishioka, et al.
  Pubblicazione: (2026)
• Association Between Baseline Neutrophil Count and Febrile Neutropenia Following Docetaxel and Ramucirumab With Prophylactic Pegfilgrastim
  di: Tomonori Makiguchi, et al.
  Pubblicazione: (2025)